35Pharma Acquired by GSK | Healthcare M&A Deal

GSK has completed the acquisition of 35Pharma, a medical devices business in Canada, for $950m. GSK acquisitions bring 35Pharma’s protein-based therapeutics platform into its respiratory, immunology and inflammation pipeline, centered on HS235 for pulmonary hypertension. The add on acquisition is designed to expand options for pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction, with HS235 targeting improved selectivity and potential metabolic benefits. This strategic acquisition is an add on acquisition by a strategic buyer, with proof-of-concept trials expected to begin soon and a reported deal value of $950m.